Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 14, Issue 5, Pages 1161-1174
Publisher
Informa UK Limited
Online
2018-03-31
DOI
10.1080/21645515.2018.1457595
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging experience with meningococcal serogroup B protein vaccines
- (2017) Daniela Toneatto et al. Expert Review of Vaccines
- Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults
- (2017) Terry Nolan et al. Open Forum Infectious Diseases
- The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection
- (2016) Ray Borrow et al. Expert Review of Vaccines
- The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines
- (2016) Stephen I. Pelton JOURNAL OF ADOLESCENT HEALTH
- Clinical experience with the meningococcal B vaccine, Bexsero ® : Prospects for reducing the burden of meningococcal serogroup B disease
- (2016) Philip S. Watson et al. VACCINE
- Neisseria meningitidisinfection: who, when and where?
- (2015) Elena Gianchecchi et al. Expert Review of Anti-Infective Therapy
- Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents
- (2015) Xavier Saez-Llorens et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers
- (2015) Jamie Findlow et al. VACCINE
- Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents
- (2015) Xavier Saez-Llorens et al. Human Vaccines & Immunotherapeutics
- Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America
- (2014) R. ABAD et al. EPIDEMIOLOGY AND INFECTION
- Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents
- (2014) Roger Baxter et al. JOURNAL OF PEDIATRICS
- Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents
- (2014) Roger Baxter et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative
- (2013) Marco Aurélio P Sáfadi et al. Expert Review of Vaccines
- Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
- (2013) Timo Vesikari et al. LANCET
- Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study
- (2012) María Elena Santolaya et al. LANCET
- Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents
- (2012) Robert M. Jacobson et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Meningococcal disease: Clinical presentation and sequelae
- (2012) David Pace et al. VACCINE
- Importance of circulating antibodies in protection against meningococcal disease
- (2012) Kim S. Erlich et al. Human Vaccines & Immunotherapeutics
- Development of an Automated, High-Throughput Bactericidal Assay That Measures Cellular Respiration as a Survival Readout for Neisseria meningitidis
- (2011) Puiying A. Mak et al. Clinical and Vaccine Immunology
- The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans
- (2011) Daniela Toneatto et al. Human vaccines & immunotherapeutics
- Meningococcal Disease: Shifting Epidemiology and Genetic Mechanisms That May Contribute to Serogroup C Virulence
- (2011) Jessica R. MacNeil et al. Current Infectious Disease Reports
- Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates
- (2010) Alan Kimura et al. Clinical and Vaccine Immunology
- Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy
- (2010) Jamie Findlow et al. CLINICAL INFECTIOUS DISEASES
- Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention
- (2010) Marco Aurélio Palazzi Sáfadi et al. NEUROLOGICAL RESEARCH
- Immunogenicity of 2 Investigational Serogroup B Meningococcal Vaccines in the First Year of Life
- (2010) Matthew D. Snape et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus
- (2010) Marzia M. Giuliani et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now